FMBA begins trials of its coronavirus vaccine
On July 19, the Federal Biomedical Agency began clinical trials of its anticoid vaccine, according to the FMBA website.
The department has received the appropriate permission from the Russian Ministry of Health.
200 people from 18 to 60 years old will take part in the research.
As a reminder, the FMBA scientific center received a patent for the drug “Mir-19” on April 11. Its name stands for small interfering RNA. The drug is expected to inhibit the replication of the virus and prevent the most severe forms of COVID-19.
Last week it was reported that the drug will be relevant for the British and Indian strains of the coronavirus.